1. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. Issue 10 (October 2022) Authors: Herman, Gary A; O'Brien, Meagan P; Forleo-Neto, Eduardo; Sarkar, Neena; Isa, Flonza; Hou, Peijie; Chan, Kuo-Chen; Bar, Katharine J; Barnabas, Ruanne V; Barouch, Dan H; Cohen, Myron S; Hurt, Christopher B; Burwen, Dale R; Marovich, Mary A; Musser, Bret J; Davis, John D; Turner, Kenneth C; Mahmood,... Journal: Lancet infectious diseases Issue: Volume 22:Issue 10(2022) Page Start: 1444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LB4. Casirivimab and Imdevimab for Treatment of Hospitalized Patients With COVID-19 Receiving Low Flow or No Supplemental Oxygen. (4th December 2021) Authors: Mylonakis, Eleftherios; Somersan-Karakaya, Selin; Sivapalasingam, Sumathi; Ali, Shazia; Sun, Yiping; Bhore, Rafia; Mei, Jingning; Miller, Jutta; Cupelli, Lisa; Hooper, Andrea T; Hamilton, Jennifer D; Pan, Cynthia; Pham, Viet; Zhao, Yuming; Hosain, Romana; Mahmood, Adnan; Davis, John D; Turner, Ke... Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S809 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗